Evidence map›Paper›PMID 40618000›Full record

ArticleDermatology and therapy2025

Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis.

Ao Shi, Yuan Shu, Joe El Haddad, Shuqin Wu, Karen Smayra, Shivon Mirza Sudesh, Mohammed Majd Mourad, Armin Farzad, Nathanael Yap, Efstathia Andrikopoulou and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ao Shi *Faculty of Medicine, St. George's, University of London, London, UK.
Yuan Shu *The Second Clinical Medical College, Nanchang University, Nanchang, China.
Joe El HaddadFaculty of Medicine, St. George's, University of London, London, UK.
Shuqin WuThe Second Clinical Medical College, Nanchang University, Nanchang, China.
Karen SmayraFaculty of Medicine, St. George's, University of London, London, UK.
Shivon Mirza SudeshFaculty of Medicine, St. George's, University of London, London, UK.
Mohammed Majd MouradFaculty of Medicine, St. George's, University of London, London, UK.
Armin FarzadFaculty of Medicine, St. George's, University of London, London, UK.
Nathanael YapFaculty of Medicine, St. George's, University of London, London, UK.
Efstathia AndrikopoulouDivision of Cardiovascular Disease, Harborview Medical Center, University of Washington, Seattle, WA, USA.
Qi LiuWafic Said Molecular Cardiology Research Laboratory, The Texas Heart Institute, Houston, TX, USA.
Pengyang LiDivision of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. leelpy0109@gmail.com.
Ying TuDepartment of Dermatology, The First Affiliated Hospital of Kunming Medical University, Kunming, China. tuying721205@126.com.ORCID http://orcid.org/0000-0003-4751-7528

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSystemic immunomodulatory treatments may affect cardiovascular and renal outcomes in patients with chronic plaque psoriasis. We conducted a network meta-analysis (NMA) to compare these outcomes of systemic treatments for plaque psoriasis.

methodsDatabases were searched from inception through June 1, 2023. We conducted duplicate study selection, data extraction, bias assessment risk, and NMA evidence certainty assessment and analyses. Outcomes included proportion of participants achieving Psoriasis Area and Severity Index (PASI) 75 and/or 90 and those with (1) total cardiovascular events, (2) major adverse cardiovascular events (MACE), (3) other cardiovascular events, and (4) total renal events.

resultsWe included 68 randomized clinical trials (n = 34,414 patients). Compared with placebo, bimekizumab (odds ratio [OR] 101.12, 95% confidence interval [CI] 34.26-301.46, surface under the cumulative ranking curve [SUCRA] 27, high certainty) was the top treatment demonstrating better PASI 75 and had reduced total cardiovascular events (OR 0.06, 95% CI 0-0.80, SUCRA 89, moderate certainty). Ixekizumab (OR 86.92, 95% CI 39.06-199.66, SUCRA 15, high certainty) showed better PASI 90 rates but was associated with increased MACE over placebo (OR 3.26, 95% CI 1.26-9.31, SUCRA 26, high certainty) and bimekizumab (OR 31.92, 95% CI 2.01, 1123.25), moderate certainty). Renal outcomes were similar among groups.

conclusionBimekizumab showed better therapeutic efficacy scores and safety profile than other agents. Ixekizumab may increase cardiovascular risk and should be used with caution. Reliable long-term safety data of the treatments analyzed here require assessing non-randomized studies and examining postmarketing reports from regulatory agencies.

trial registrationPROSPERO (CRD42022381489).

Indexed as

BiologicsCardiovascular outcomeNetwork meta-analysisPsoriasisSystemic immunomodulatory treatment

Identifiers

PMID40618000
PMCPMC12354450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.